Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease

Movement Disorders

Volumn 24, Issue 4, 2009, Pages 541-550

  Hauser, Robert A ^a   Panisset, Michel ^b   Abbruzzese, Giovanni ^c   Mancione, Linda ^d   Dronamraju, Nalina ^d   Kakarieka, Algirdas ^d   Ahmed, Anwar ^e   Albanese, Alberto ^f   Bonuccelli, Ubaldo ^g   Cakmur, Raif ^h   Chou, Kelvin ⁱ   Cloutier, Martin ^j   Cunha, Luis ^k   Desai, Hiren ^l   Djaldetti, Ruth ^m   Dostal, Vaclav ⁿ   Elibol, Bulent ^o   Emre, Murat ^p   Fiszer, Urszula ^q   Friedman, Joseph ⁱ   Giladi, Nir ^r   Gollomp, Stephen ^s   Goodridge, Alan ^t   Grimes, David ^u   Gurevich, Tanya ^r   Guttman, Mark ^v   Hassin, Sharon ^w   Huang, Zhigao ^x   Hutchman, Robert ^y   Jimenez Shahed, Joohi ^z   Kanovsky, Petr ^aa   King, David ^ab   Klein, Colin ^ac   Kraft, Scott ^ad   Lafontaine, Anne Louise ^ae   Lopiano, Leonardo ^af   Lewitt, Peter ^ag   Mach, Vojtech ^ah   Mazzeo, Paul ^ai   Meco, Giuseppe ^aj   Mendis, Tilak ^ak   Morgante, Letterio ^al   Opala, Grzegorz ^am   Pezzoli, Gianni ^an   Pourcher, Emmanuelle ^ao   Rabey, Jose Martin ^ac   Rajput, Alexander ^ap   Rivest, Jean ^aq   Rosa, Mario Miguel ^ar   Rossen, Michael ^as   Rudzinska, Monika ^at   Ruggieri, Stefano ^au   Ruzicka, Evzen ^av   Sauter, Michael ^aw   Silver, Dee ^ax   Stewart, Dwight ^ab   Sunter Jr , William ^ay   Uitti, Ryan ^az   Veloso, Felix ^ba   Zappia, Mario ^bb   Zesiewicz, Theresa ^a   more..

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF GENOA   (Italy)

^d NOVARTIS PHARMA AG   (Switzerland)

^e ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^f DEPARTMENT OF NEUROSURGERY   (Italy)

^g Versilia Hospital   (Italy)

^h DOKUZ EYLUL UNIVERSITY   (Turkey)

ⁱ NeuroHealth   (United States)

^j Neuro Rive Sud   (Canada)

^k CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^l Hiren Desai Professional Corporation   (Canada)

^m RABIN MEDICAL CENTER   (Israel)

ⁿ Pardubice Regional Hospital   (Czech Republic)

^o HACETTEPE UNIVERSITY   (Turkey)

^p ISTANBUL UNIVERSITY   (Turkey)

^q MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^r TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^s LANKENAU HOSPITAL   (United States)

^t Eastern Health Canada   (Canada)

^u UNIVERSITY OF OTTAWA   (Canada)

^v Centre for Movement Disorders   (Canada)

^w SHEBA MEDICAL CENTER   (Israel)

^x UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^y Neuroresearch Incorporated   (United States)

^z BAYLOR COLLEGE OF MEDICINE   (United States)

^aa UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^ab Baylor College of Medicine ^*

^ac Asaf Harofe Medical Center   (Israel)

^ad UNIVERSITY OF CALGARY   (Canada)

^ae MONTREAL GENERAL HOSPITAL   (Canada)

^af UNIVERSITY OF TURIN   (Italy)

^ag Clinical Neuroscience Center   (United States)

^ah Faculty Hospital   (Czech Republic)

^ai Faculty Hospital ^*  (Italy)

^aj SAPIENZA UNIVERSITY OF ROME   (Italy)

^ak Parkinson's and Neurodegenerative Disorders Clinic   (Canada)

^al UNIVERSITY OF MESSINA   (Italy)

^am Katedra i Klinika Neurologii Wieku Podesz ego SAM SP Centralny Szpital Kliniczny ul Medyków 14   (Poland)

^an PARKINSON INSTITUTE   (Italy)

^ao Quebec Memory and Motor Skills Disorders Research Center   (Canada)

^ap ROYAL UNIVERSITY HOSPITAL   (Canada)

^aq CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^ar HOSPITAL DE SANTA MARIA   (Portugal)

^as Springfield Neurology Associates LLC   (United States)

^at Krakowska Akademia Neurologii   (Poland)

^au IRCCS NEUROMED   (Italy)

^av CHARLES UNIVERSITY   (Czech Republic)

^aw Westmoreland Neurology   (United States)

^ax Westmoreland Neurology Associates ^*  (United States)

^ay Melbourne Internal Medicine Associates   (United States)

^az MAYO CLINIC   (United States)

^ba Saskatchewan Health Authority   (Canada)

^bb Policlinico di Catania   (United States)

more..

Author keywords

Entacapone; Levodopa; Parkinson's disease; Stalevo; Treatment; UPDRS

Indexed keywords

CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; DOMPERIDONE; SINEMET IR; TRIMETHOBENZAMIDE; UNCLASSIFIED DRUG; ANTIPARKINSON AGENT; CARBIDOPA; CATECHOL DERIVATIVE; ENTACAPONE; LEVODOPA; NITRILE;

ADULT; AGED; ARTICLE; BACKACHE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; NAUSEA; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; WEIGHT REDUCTION; COMPARATIVE STUDY; DRUG COMBINATION; HOSPITALIZATION; METHODOLOGY; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CARBIDOPA; CATECHOLS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NITRILES; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX;

EID: 67651034799     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22343     Document Type: Article

References (28)

1. Birkmayer W, Hornykiewicz O. Der L-3,4-Dioxyphenylalanin (= DOPA)-Effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 1961;73:787-788.
2. Barbeau A, Sourkes TL, Murphy GF. Les catécholamines dans la maladie de Parkinson. In: de Ajuriaguerra J, editor. Monoamines et système nerveux central. Geneva: Georg & Cie SA; 1962. p 247-262.
3. Cotzias GC, van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. New Engl J Med 1967;276: 374-379.
4. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol 1969;21:343-354.
5. Olanow CW. The scientific basis for the current treatment of Parkinson's disease. Annu Rev Med 2004;55:41-60.
6. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. New Engl J Med 1984; 310:483-488.
7. Lieberman A, Goodgold A, Jonas S, Leibowitz M. Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease. Neurology 1975;25:911-916.
8. Markham C, Diamond SG, Treciokas LJ. Carbidopa in Parkinson disease and in nausea and vomiting of levodopa. Arch Neurol 1974;31:128-133.
9. Boomsma F, Meerwaldt JD, Man in't Veld AJ, Hovestadt A, Schalekamp MA. Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa. J Neurol 1989;236:223-230.
10. Tolosa ES. Current therapy for Parkinson's disease: levodopa - the gold standard. Clin Neuropharmacol 1998;21(suppl 1):S1-S4.
11. Dunner DL, Brodie HK, Goodwin FK. Plasma DOPA response to levodopa administration in man: effects of a peripheral decarboxylase inhibitor. Clin Pharmacol Ther 1971;12:212-217.
12. Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 1996;19:283-296.
13. Brooks DJ, Sagar H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatr 2003;74:1071-1079.
14. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-755.
15. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002;105:245-255.
16. Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998;51: 1309-1314.
17. Olanow CW, Kieburtz K, Stern M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol 2004;61: 1563-1568.
18. Hauser RA. Levodopa/carbidopa/entacapone (Stalevo). Neurology 2004;62(1 suppl 1):S64-S71.
19. Olanow CW. Movement disorders: a step in the right direction. Lancet Neurol 2006;5:3-5.
20. Smith LA, Jackson MJ, Al-Barghouthy G, Rose S, Kuoppamaki M, Olanow W, Jenner P. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord 2005;20:306-314.
21. Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord 2006;21:1200-1207.
22. Gordin A, Kaakkola S, Teravainen H. Clinical advantages of COMT inhibition with entacapone - a review. J Neural Transm 2004;111:1343-1363.
23. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006;63:1756-1760.
24. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. New Engl J Med 2004;351:2498-2508.
25. Brooks DJ. Safety and tolerability of COMT inhibitors. Neurology 2004;62(1 suppl 1):S39-S46.
26. Brooks DJ, Leinonen M, Kuoppamaki M, Nissinen H. Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease. J Neural Transm 2008;115:843-849.
27. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-687.
28. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005;20:224-230.